Pfizer could face £502M bill if it comes up short in U.K. patent appeal for Lyrica

Pfizer could be on the hook for £502 million in National Health Service spending on Lyrica if a patent appeal fails, a new study found. The patent, covering Lyrica's use as a pain treatment, was invalidated in 2015, but Pfizer continued to defend it aggressively as it appealed—and now, decision time is near.Original Article